NCT05910827 2026-04-15A Phase Ib/II Study of an Anti-HER3 Antibody, HMBD-001, With Cetuximab +/- Docetaxel in Advanced Squamous Cell CancersHummingbird BiosciencePhase 1/2 Recruiting398 enrolled